Arcus Biosciences, Inc.

NYSE:RCUS Stok Raporu

Piyasa değeri: US$1.4b

Arcus Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Arcus Biosciences CEO'su Terry Rosen, May2015 tarihinde atandı, in görev süresi 9.5 yıldır. in toplam yıllık tazminatı $ 10.12M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.4% maaş ve 93.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 4.08% ine doğrudan sahiptir ve bu hisseler $ 57.83M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 4.7 yıldır.

Anahtar bilgiler

Terry Rosen

İcra Kurulu Başkanı

US$10.1m

Toplam tazminat

CEO maaş yüzdesi6.4%
CEO görev süresi9.5yrs
CEO sahipliği4.1%
Yönetim ortalama görev süresi4.3yrs
Yönetim Kurulu ortalama görev süresi4.7yrs

Son yönetim güncellemeleri

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Recent updates

Arcus Biosciences: Advancing On Several Fronts

Oct 29

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Sep 23

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 15
Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Aug 19
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

May 10
Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18
Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Dec 15

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Nov 30
Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Nov 20

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Aug 29

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08
Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05
Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

CEO Tazminat Analizi

Terry Rosen'un ücretlendirmesi Arcus Biosciences'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$249m

Mar 31 2024n/an/a

-US$231m

Dec 31 2023US$10mUS$650k

-US$307m

Sep 30 2023n/an/a

-US$293m

Jun 30 2023n/an/a

-US$287m

Mar 31 2023n/an/a

-US$279m

Dec 31 2022US$9mUS$350k

-US$267m

Sep 30 2022n/an/a

US$80m

Jun 30 2022n/an/a

US$67m

Mar 31 2022n/an/a

US$58m

Dec 31 2021US$9mUS$367k

US$53m

Sep 30 2021n/an/a

-US$278m

Jun 30 2021n/an/a

-US$199m

Mar 31 2021n/an/a

-US$168m

Dec 31 2020US$6mUS$326k

-US$123m

Sep 30 2020n/an/a

-US$88m

Jun 30 2020n/an/a

-US$112m

Mar 31 2020n/an/a

-US$95m

Dec 31 2019US$2mUS$340k

-US$85m

Sep 30 2019n/an/a

-US$80m

Jun 30 2019n/an/a

-US$69m

Mar 31 2019n/an/a

-US$54m

Dec 31 2018US$1mUS$295k

-US$50m

Sep 30 2018n/an/a

-US$51m

Jun 30 2018n/an/a

-US$63m

Mar 31 2018n/an/a

-US$59m

Dec 31 2017US$427kUS$315k

-US$53m

Tazminat ve Piyasa: Terry 'nin toplam tazminatı ($USD 10.12M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.64M ).

Tazminat ve Kazançlar: Terry şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Terry Rosen (64 yo)

9.5yrs

Görev süresi

US$10,120,945

Tazminat

Dr. Terry J. Rosen, Ph D., serves as Director at PACT Pharma, Inc. He co-founded Arcus Biosciences, Inc. in 2015 and has been its Chief Executive Officer since May 2015. Dr. Rosen has been the Chairman of...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Terry Rosen
Co-Founder9.5yrsUS$10.12m4.08%
$ 57.8m
Juan Jaen
Co- Founder & President9.5yrsUS$4.75m1.56%
$ 22.1m
Robert Goeltz
Principal Financial Officer & CFO4.3yrsUS$3.59m0.017%
$ 239.6k
Jennifer Jarrett
Chief Operating Officer4.1yrsUS$4.74m0.082%
$ 1.2m
Dimitry Nuyten
Chief Medical Officer2.3yrsUS$3.69m0.022%
$ 312.9k
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno dataVeri yokVeri yok
Alexander Azoy
VP of Finance & Principal Accounting Officer1.7yrsVeri yok0.0032%
$ 45.8k
Jonathan Yingling
Chief Scientific Officer3.8yrsVeri yokVeri yok
Carolyn Tang
General Counsel & Corporate Secretary6.3yrsUS$2.92m0.052%
$ 742.6k
Holli Kolkey
Vice President of Corporate Communicationsno dataVeri yokVeri yok
Yvonne Gehring
Senior Vice President of Human Resources & Operationsno dataVeri yokVeri yok
Eric Matthews
Chief Commercial Officer5.4yrsVeri yokVeri yok

4.3yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: RCUS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Terry Rosen
Co-Founder9.6yrsUS$10.12m4.08%
$ 57.8m
K. Christopher Garcia
Co-Founder & Member of Scientific Advisory Boardno dataVeri yokVeri yok
Yasunori Kaneko
Lead Independent Director9.5yrsUS$503.21k0.16%
$ 2.3m
Kathryn Falberg
Independent Director7.2yrsUS$479.08k0.16%
$ 2.3m
Andrew Perlman
Independent Director3.9yrsUS$455.83k0.023%
$ 324.4k
Jeffrey Bluestone
Chairman of Scientific Advisory Boardno dataVeri yokVeri yok
C. Machado
Independent Director4.9yrsUS$455.83k0.018%
$ 261.9k
David Lacey
Independent Director & Member of Scientific Advisory Board4.5yrsUS$500.83k0.054%
$ 763.4k
Antoni Ribas
Independent Director & Member of Scientific Advisory Board9.8yrsUS$470.83k0.033%
$ 472.8k
Merdad Parsey
Director4.3yrsVeri yokVeri yok
Nicole Lambert
Independent Director3.3yrsUS$450.83k0.015%
$ 217.5k
Stefani Spranger
Member of Scientific Advisory Board4.2yrsVeri yokVeri yok

4.7yrs

Ortalama Görev Süresi

63.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: RCUS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.7 yıldır).